Cortiject (dexamethasone palmitate) / Santen - LARVOL DELTA

Tiny dexamethasone palmitate nanoparticles for intravitreal injection: optimization and in vivo evaluation. (PubMed, Int J Pharm) - "After breakdown of the blood-retinal barrier (BRB) induced by injection of rhVEGF165 with carrier protein, DXP nanoparticles induced a restoration of the BRB 1 month after their intravitreal injection. However, their efficacy was limited in time most probably by clearance of DXP nanoparticles after 2 months due to their small size."

Journal • Preclinical • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders

Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. (PubMed, Clin Rheumatol) - "Corticosteroid therapy represents the first line of treatment, including liposome-incorporated dexamethasone palmitate (liposteroid)...Cyclophosphamide, azathioprine, hydroxychloroquine, mycophenolate mofetil, and mesenchymal cell transplantation have been attempted to improve outcome and reduce side effects. Controlled studies are needed to assess the optimal combination of medications, which are effective to control the disease."

Journal • Review • Hematological Disorders • Immune Modulation • Inflammation • Rare Diseases • Transplantation

Successful unrelated cord blood transplantation for extensive meningeal juvenile xanthogranuloma developing after treatment of Langerhans cell histiocytosis in a child (PubMed, Rinsho Ketsueki) - "The JXG masses were not responsive to prednisolone, which was injected locally, radiotherapy (24 Gy), and chemotherapy (2-chlorodeoxy-adenosine)...Four months after CBT, the patient was treated with infliximab (Remicade) and dexamethasone palmitate (Limethasone). The size of the intracranial JXG masses gradually decreased after u-CBT and disappeared after 4 years. Currently, the patient is doing well at the age of 25 years and is receiving androgen replacement therapy."

Clinical • Journal • Graft versus Host Disease • Immunology • Langerhans Cell Histiocytosis • Transplantation

Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. (PubMed, J Control Release) - "Their passive accumulation in arthritic joints leads to disease remission and recovery of the joint structure at a dose of 1 mg/kg dexamethasone, without any adverse effects. Dexamethasone palmitate nanoparticles are promising in the treatment of inflammation in rheumatoid arthritis with a very significant difference occurring at the late stage of inflammation allowing to prevent the progression of the disease."

Journal • Immunology • Rheumatoid Arthritis • Rheumatology

NANOSCALE LIPOPHILIC PRODRUGS OF DEXAMETHASONE WITH ENHANCED PHARMACOKINETICS. (PubMed, Mol Pharm) - "Here, we successfully formulated a prodrug of dexamethasone, dexamethasone palmitate (DXP), into nanoparticles stabilized by the sole presence of distearoyl- sn-glycero-3-phosphoethanolamine- N-[methoxy(poly(ethylene glycol))-2000] (DSPE-PEG). The release of DXM from DXP-NPs in plasma was clearly controlled up to 18 hours compared to the free drug which was rapidly eliminated from plasma after administration. In conclusion, a novel type of nanoparticle combining the advantages of prodrugs and nanoparticles was designed, easy to produce with a high loading efficiency and leading to modified pharmacokinetics and tissue distribution after IV administration."

Journal • PK/PD data

A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis. (PubMed, AAPS PharmSciTech) - "It was confirmed that intravenous injection of DMP-MMs exhibited advantages in alleviating joint inflammation compared with the emulsion system. Composed of pharmaceutical adjuvants only, the nanoscale mixed micelles seem a promising carrier system for the RA treatment with lipophilic drugs."

Journal

Dexamethasone palmitate is a feasible option for the treatment of chronic graft-vs-host disease, particularly with macrophage hyperactivation. (PubMed, Pediatr Transplant) - No abstract available.

Journal

Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment. (PubMed, Pharm Res) - "SA-modified liposomal DP was a promising candidate for RA-targeting treatment through the neutrophil-mediated drug delivery system."

Journal

Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome. (PubMed, Int J Hematol) - No abstract available.

Clinical • Journal

HEMATOPOIETIC CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE/BUSULFAN AND FLUDARABINE/MELPHALAN FOR PRIMARY IMMUNODEFICIENCY DISEASES (EBMT 2019) - "Background: Primary immunodeficiency disease (PID) is congenital disorders of innate or acquired immune system. The RIC-HCT using FluBU or FluMel was advantagous for neutrophil engraftment, and FluBU for SCID and FluMel for CID with immune dysregulation may be an effective opinion. FluBU regimen needs to be improved for secondary graft failure in non-SCID. Prevention of HLH after transplantation using dexamethasone palmitate will be considered."